Market Intelligence, Clinical Progress, and High-Purity Reagents for Apoptosis-Targeted Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BAX drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BAX Recombinant Protein (Full-length, ΔTM, BH3 Mutant, Constitutively Active Mutants). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native folding. | View BAX Products |
| Conformational Variant | BAX Activated Mutant (Cys-reactive variants, e.g., S184V). For pore-formation studies. Theoretical MW verified. | View BAX Products |
| Gene Delivery | BAX Promise-ORF Lentivirus with mCherry reporter. Full-length ORF for stable cell lines. Titers >1×10^8 TU/mL. | View BAX Products |
| Benchmark Ab | Anti-BAX (Recombinant Rabbit mAb) / Anti-BAX (Biosimilar/Control). Positive control for Western, IP, and conformational assays. | View BAX Products |
| Validator | BAX siRNA Set (3 unique sequences). For knockdown verification and specificity controls. | View BAX Products |
| Related Target: BAK1 | BAK1 (BCL2L7). Synergistic MOMP effector and essential paralog for cross-selectivity screening. | View BAK1 Products |
| Related Target: BCL2 | BCL-2. Anti-apoptotic antagonist; essential for counter-screening and combination therapy logic. | View BCL2 Products |
| Related Target: BCL2L1 | BCL-XL (BCL2L1). Dominant negative regulator; required for selectivity profiling of BAX activators. | View BCL2L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation-specific activation & oligomerization (Inactive vs Active) | WT & constitutively active mutants sequence verified; available for SPR / BLI / analytical ultracentrifugation. |
| BAX vs BAK paralog selectivity | Human BAX & BAK1 ortholog proteins with >95% purity; mass spec identity confirmed. |
| Liposome permeabilization / MOMP reconstitution | Endotoxin-controlled (<1 EU/µg) protein batch suitable for membrane-insertion assays. |
| Target engagement & off-target specificity | Validated siRNA included for loss-of-function specificity checks. |
| Mitochondrial translocation studies | Full-length ORF Lentivirus with fluorescent tags; HEK293 packaging for native post-translational modification. |
Live BAX R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for BAX therapeutics is intensifying, with major players shifting focus from traditional BCL-2 inhibitor monotherapy to direct BAX activation and combinatorial apoptosis induction. As first-generation apoptosis-inducing therapies (e.g., venetoclax) face resistance via BAX/BAK pathway alterations, the next wave of R&D is targeting direct BAX conformational activators (e.g., BTSA1, BAM7 by Albert Einstein College and Dana-Farber) and selective BAX inhibition for neuroprotection (e.g., in ischemic stroke and neurodegeneration). Key modalities include small molecule direct activators, stapled BH3 peptides, BCL-2/BCL-XL inhibitor combos, and gene therapy approaches.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Direct Activators | Albert Einstein College (BTSA1), Dana-Farber (BAM7), academic consortia, emerging biotech | Refractory Solid Tumors, AML, Hematologic Malignancies | Conformational Activation Assay (Need native full-length BAX mutants and high-purity WT protein) |
| Small Molecule Inhibitor | Academic & Biotech spin-offs | Ischemic Stroke, Neurodegeneration | Pore-formation Assay (Need structural integrity & theoretical MW verified protein) |
| Stapled BH3 Peptides / Peptide Therapeutics | Academic / Biotechnology partners, peptide engineering companies | Refractory Cancers, Hematological Malignancies | Competitive Binding Assay (Need BCL-2 family protein panel) |
| BCL-2/BCL-XL Inhibitor Combo | AbbVie, Roche / Genentech | CLL, AML, Venetoclax-resistant AML, Solid Tumors | Combination Apoptosis Assay (Need BAX overexpression lentivirus and siRNA for BAX/BAK1 specificity) |
| Gene Therapy (BAX overexpression) | Viral vector specialists | Resistant Cancers | Expression Validation (Need high-titer Lentivirus with reporter) |
Molecular Differentiation & Assay Strategy
Developing best-in-class BAX modulators requires overcoming unique challenges due to the conformational switch nature of BAX.
- Affinity & Binding Mode: Activators must bind the N-terminal trigger site (not the BH3-binding groove) to avoid sequestration by anti-apoptotic proteins. Assays: SPR/BLI with full-length BAX (closed vs open conformation).
- Mechanism of Action: Must induce N-terminal exposure (6A7 epitope), α9 helix membrane insertion, and subsequent homooligomerization. Assays: Liposome permeabilization (ANTS/DPX release), cross-linking oligomerization gel.
- Selectivity over BAK1: BAX and BAK1 are functionally redundant; drugs should ideally spare BAK1 to maintain normal tissue homeostasis. Assays: Paralog counter-screen with high-purity BAX and BAK1 proteins.
- Membrane Insertion Kinetics: α9 helix insertion into mitochondrial outer membrane is critical. Assays: Cardiolipin-containing liposome assays, cytochrome c release detection.
- Key Mutations: BAX mutations (rs555248599 in plasmacytoma, rs36017265, and loss-of-heterodimerization mutant in T-ALL) are implicated in drug resistance and can be modeled using customized mutant proteins.
TarMart provides sequence-verified full-length and mutant BAX proteins, high-purity monomers (>95%) with endotoxin control, lentivirus for cell line construction, and a complete panel of BCL2 family proteins for selectivity profiling.
Related Target Cross-Selling
To support comprehensive apoptosis pathway research and combination therapy screening, the following related targets are recommended for cross-selling:
- BAK1 (BCL2L7): Redundant MOMP effector; essential for BAX activator specificity screening.
- BCL2L1 (BCL-XL): Primary anti-apoptotic antagonist; required for competitive binding and combination assays.
- BCL2 (BCL-2): Key anti-apoptotic target for venetoclax and resistance studies.
- BIM (BCL2L11): BH3-only direct activator of BAX; used as positive control in activation assays.
- MCL1: Another critical anti-apoptotic node; common in combination therapy.
- Cytochrome C (CYCS): Downstream readout for MOMP functional assays.
- PUMA (BBC3): BH3-only protein; positive control for BAX activation efficiency.